Industry Roundup: Nutrilite, No-GMO Similac, Supreme Court, Herbalife VPs
This article was originally published in The Tan Sheet
Executive Summary
Nutrilite ingredient granulation expands; GMO-free Similac debuts; Herbalife adds corporate VPs; Supreme Court likely not taking cosmetics preemption case; OTC device claim nixed in U.K.; and more news in brief.
You may also be interested in...
Supreme Court Asked To Consider Pre-emption In Drug Vs. Cosmetic Litigation
The Supreme Court asks the Solicitor General for an amicus in a case examining whether FDA regulation pre-empts state litigation on the cosmetics/drugs regulatory divide. The case could have implications for the personal care industry as states increasingly claim oversight by clarifying FDA’s division between drugs and cosmetics.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.